STOCK TITAN

Protalix BioTherapeutics Inc. - PLX STOCK NEWS

Welcome to our dedicated news page for Protalix BioTherapeutics (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix BioTherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Protalix BioTherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Protalix BioTherapeutics's position in the market.

Rhea-AI Summary
Protalix BioTherapeutics, Inc. reports fiscal year 2023 financial results and business update, including regulatory approvals for Elfabrio and progress on PRX-115 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
earnings
-
Rhea-AI Summary
Protalix BioTherapeutics, Inc. (PLX) to release fiscal year 2023 financial results and business update on March 14, 2024. Conference call and webcast scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
earnings
-
Rhea-AI Summary
Protalix BioTherapeutics, Inc. (PLX) will present at the 2024 BIO CEO & Investor Conference on February 26, 2024. Management will give a corporate overview and participate in one-on-one meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
Rhea-AI Summary
Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced the approval of Elfabrio® for the treatment of Fabry disease by the U.S. FDA and the European Medicines Agency. The company is making progress in pipeline programs and strengthening its operations for commercial products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary
Protalix BioTherapeutics reports financial results for Q3 2023, with revenues of $10.2 million, an increase of 16% compared to the same period last year. The company's approved drug, Elfabrio, is being commercialized by Chiesi Global Rare Diseases in the US and EU. Protalix is also progressing its product candidate PRX-115 for severe gout treatment. The company's balance sheet remains strong with cash equivalents of $41.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.38%
Tags
earnings
-
Rhea-AI Summary
Protalix BioTherapeutics, Inc. will release its financial results for the third quarter ended September 30, 2023 and provide a business update on November 6, 2023. The company will host a conference call and webcast to discuss the financial results and recent corporate and regulatory developments. The conference call will take place on November 6, 2023, at 8:30 a.m. EST. The webcast will be available on the company's website. Participants are requested to access the call at least 15 minutes ahead of the conference to register and install necessary audio software.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
earnings
Rhea-AI Summary
Protalix BioTherapeutics issues statement on current security situation in Israel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.71%
Tags
none
-
Rhea-AI Summary
Protalix BioTherapeutics appoints Eliot Richard Forster, Ph.D. as Chairman of the Board of Directors, effective September 14, 2023. Zeev Bronfeld to retire from the Board. Forster's extensive experience in the life sciences industry is expected to strengthen the company's research and development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
management
-
Rhea-AI Summary
Protalix BioTherapeutics appoints Eliot Richard Forster, Ph.D. as Chairman of the Board of Directors, effective September 14, 2023. Zeev Bronfeld to retire from the Board. Forster's extensive experience in the life sciences industry is expected to strengthen the company's research and development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
management
Rhea-AI Summary
Protalix BioTherapeutics announces that Dror Bashan, the Company's President and CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
Protalix BioTherapeutics Inc.

NYSE:PLX

PLX Rankings

PLX Stock Data

92.05M
64.75M
9.77%
14.05%
9.14%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
2 Snunit St Science Park Pob 455

About PLX

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase